MDMA therapy company Lykos raises $100M in Series A funding as it eyes FDA approval

MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first provider of psychedelic-assisted therapy PTSD.

Previous post Agilon Health’s stock suffers record plunge after revenue, margin outlook cuts
Next post CVS sees 2024 Medicare Advantage enrollment beating expectations